Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anwaar M Saeed, MD
UPMC Hillman Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Anwaar Saeed, MDRecruiting - Houston Methodist Neal Cancer Center
Houston, Texas, United States
Maen Abdelrahim, MDNot, yet, recruiting - Mays Cancer Center, Ut Health San Antonio
San Antonio, Texas, United States
Sukeshi Patel Arora, MDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2024
- Primary completion
- 31 Dec 2026
- Completion
- 30 Apr 2027
- Last update posted
- 6 Nov 2025
- Registered enrollment
- 40
- Registry id
- NCT06698250
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.